Sichenzia Ross Ference Kesner LLP Represents XTL Biopharmaceuticals Ltd. in $2.5 Million Registered Direct Offering
Press Release – New York, NY – February 27, 2017 – Sichenzia Ross Ference Kesner LLP announced today that it has represented XTL Biopharmaceuticals, Ltd. (NASDAQ: XTLB) (TASE: XTL.TA), an Israeli clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, in a registered direct offering of 1,000,000 American Depository Shares (“ADSs”) at a price of $2.50 per share and unregistered warrants to purchase 1,000,000 ADSs at an exercise price of $4.10 per ADS for gross proceeds of $2,500,000. Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering. The Sichenzia Ross Ference Kesner LLP team was led by partners Gregory Sichenzia and Avital Even-Shoshan and counsel Cheryll Calaguio.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Attorneys Mendy Piekarski and Jay Kaplowitz Achieve Successful Settlement of Cryptocurrency Lawsuit - May 21, 2018
- Sichenzia Ross Ference Kesner LLP Represents Pareteum Corporation in $6.1 Million Registered Direct Offering - May 14, 2018
- Partner Harvey Kesner Publishes Article on SEC and Cryptocurrency in Law360 - May 9, 2018